“This is such excellent news. You all were so meticulous and supportive throughout. You all were so professional and on top of things. Your perception of whose testimonials would be ideal was on point.”

General Field: Biomedical Engineering

Position at the Time of Case Filing: Postdoctoral Fellow

Country of Origin: India

State of Residence at the Time of Filing: Illinois

Approval Notice Date: November 4^th, 2021

Processing Time: 30 days (Premium Processing Requested)

---

“It’s an arduous and sometimes frustrating process, but I am more than happy with the quality and professionalism of the work being put in at this firm. Thank you for being so detail-oriented, gives the applicant a lot of confidence. You guys are truly the best in the field.”

Case Summary:

We at North America Immigration Law Group, before moving forward with any case, take utmost care in conducting a complete background check of every client who approaches us for helping them with their immigration petition to USCIS. So, when an attending hematologist and oncologist in the field of medical oncology approached us, we made certain that he received the best legal services for his I-140 NIW (National Interest Waiver) and as well as EB-1A (Alien of Extraordinary Ability) petition.

• We delivered his exceptional professional background and unique experience important to his current and future work at the USCIS.

After reviewing his credentials, we found that our client has accumulated a splendid record of success:

• He received his MBBS from India.
• His research has resulted in 4 peer-reviewed scientific articles.
• His publications have been cited a total of 78 times in at least 16 countries according to Google Scholar.
• He has conducted at least 15 reviews for at least 3 journals.
• All the above factors thereby signify that his record of publications and citations are widely acknowledged and counted upon in the field of his expertise.

Additionally, our client’s novel lymphoma and cancer treatments research addresses some of our nation’s and the world’s most pressing issues, including HIV-related lymphoma and breast cancer. His strong background in hematology and medical oncology has allowed his research to be particularly original, resulting in his success in fundamentally transforming novel lymphoma and cancer treatments research. He is particularly well-known for his contributions to new antibody approaches to lymphoma therapy.

• Our client’s work has thus been majorly significant, and his achievements are of the utmost importance due to their direct applicability in global efforts to address the global health burdens associated with cancer and lymphoma.

Additionally, he has served as the principal investigator for the National Surgical Adjuvant Breast and Bowel Project trial consortium.

• Thus, based on the originality, practicality, and importance of our client’s research endeavors, his achievements in the academic field of research have secured his reputation as an exceptional professor in the international community of medical oncology.

Leading researchers from top universities and research groups from the United States and abroad have submitted letters confirming him as an outstanding professor in his specialized field.

• Two out of five of his recommenders have the following to say about him:

“Finally, in addition to its scholarly merit, [client’s] research is also highly beneficial to the United States…Since over 1 million Americans are living with HIV today, it can be estimated that at least 100,000 Americans suffer from HIV-related lymphoma…As these populations already receive relatively less care in the American healthcare system, there is a critical need for addressing our current lack of knowledge regarding the optimal means of preventing and treating AIDS-related lymphoma. [Client] addresses this need in his research, and his work thus directly aligns with the public health interests of the United States.”

“[Client’s] research stands at the forefront of the field of medical oncology, particularly in his research into enhanced therapies for the prevention of breast cancer…Through his innovative research on the novel use of phytochemicals to prevent breast cancer, [client] has worked to directly address this imperative. The ultimate value of his research on this topic is thus wholly incalculable.”

We are certain that he is more than capable of furthering his knowledge base in the chosen field and continuing his work in the United States of America.

• The best news is that he not only received his NIW and EB1-A approvals with the help of our firm’s continuous guidance, he even received his 1-485 application approved very recently.

We thus wish him the very best in his life and success in all the endeavors that he takes up soon.

---

“Thank you so much for your help!”

Case Summary:

Initially, our client, a principal scientist with a Ph.D. in molecular oncology from Hong Kong, approached North America Immigration Law Group to help her in filing an I-140 petition under the national interest waiver visa category and within two months she decided to retain our services for another I-140 petition documentation under the alien of extraordinary ability visa category. Despite two different petition categories, we have first-hand knowledge of how to exactly file these two petitions consecutively to acquire the desired result for our clients.

Therefore, both EB-2 NIW (National Interest Waiver) and EB1-A (Alien of Extraordinary Ability) petition approvals were granted on the same day to our client. When we commenced with the attorney-client relationship agreement, the first and foremost task for our team was to evaluate her provided credentials to determine her NIW and EB1A victory respectively. We were certain that we would be able to lead her to obtain the approvals successfully.

After analyzing her background, paperwork, and the associated evidence, we were pretty much confident that they were inevitable to persuade USCIS, thus, we incorporated the following in her respective petition packets:

• The 13 peer-reviewed journal articles she published in no fewer than 6 highly ranked peer-reviewed journals in the field of oncology.
• A great record of 515 citations was acquired from her published work, proving that many other experts have utilized her findings and strategies with favorable results.
• Cited by researchers in at least 44 countries.
• She has also been invited to review and evaluate the work of her peers no fewer than 29 times, serving as major evidence of her superiority in the field.

Moreover, our client’s research is to continue using molecular biology, cancer biology, cancer immunology, cancer target discovery, and drug discovery techniques to identify mechanisms of cancer progression for the development of new drug targets and treatment strategies to improve patient survival. We deduced that her research seemed of great importance because it promotes the development of newer and more effective treatments for one of the largest causes of death around the world, cancer.

In addition, considering her other results provide improved, tailored treatment strategies for lung cancer patients, demonstrating the crucial nature of her studies for improving survival outcomes of lung cancer patients, corroborated further by four recommendation letters obtained from her fellow experts in the field. One of the letters had the below-mentioned statement.

“The importance of identifying new approaches to regulate lung cancer is crucial to curbing the impact of the disease. Lung cancer is the second most common cancer worldwide and has been among the most common cancers overall for several decades. [Client’s] research advances the development of new therapeutic drug targets for patients with lung cancer. Her work has revealed the impact of integrating molecular profiling data to obtain biological insights into formerly uncharacterized lung cancer prognostic biomarkers… Therefore, the importance of her research for advancing novel therapeutics to overcome one of the most common causes of death worldwide must be highlighted.”

Once again, we are delighted that our team was very well successful in persuading USCIS of our client’s research which is relevant to identifying new druggable targets to treat cancer patients. Thus, she achieved both the approvals on the same day, and we would generously like to thank her for trusting our law firm for the I-140 petitions and wish her well in her future endeavors.

---

“Thanks a million for your professional work on both my EB1A and NIW petitions, and I’m so satisfied.”

Case Summary:

“[Client’s] development of a DNA barcode database for herbal medicines has greatly improved the species identification capabilities of many other institutions, including governmental and industrial organizations. Her research into DNA barcoding supports the safe development and manufacturing of herbal medicines, pharmaceuticals, and supplements, thereby supporting public health on a global scale.”

“The United States has much to gain from [client’s] ongoing research, as it informs the development of herbal medicines and dietary supplements. [Client’s] work in DNA barcoding supports the quality control process during pharmaceutical manufacturing, allowing for better detection of toxic materials. These benefits for public health and nature conservation are valuable to the United States because they make the population and the environment healthier, which has positive downstream effects in countless areas.”

It is generally accepted that one of the ways of knowing a person is through their work. This is what we found was true for the recommendations of our client, a researcher in pharmacognosy from China. Of the 4 recommendation letters that she received, 2 came from independent scholars who knew her through her work. It thus became clear to us at the onset of the case preparation process that the client’s work in the area was indeed of value and substantial merit, both national and international. This is why very soon after her NIW (National Interest Waiver) approval, she received her EB1-A approval.

After the initial steps of background research and attorney-client agreement, we emplored our team to prepare her case. This meant that her academic and professional backgrounds were all used to build her petition. Some of the things we did in this process are as follows:

• We made sure that her past experience in the field was clear to the adjudicating authorities. So we showed that she is one of the few leading DNA barcoding identification experts in pharmacognosy, and she has achieved a consistent and notable record of success and influence in this area of study.
• We also showed that her work has also been directly utilized by the Chinese Pharmacopoeia Commission, thus demonstrating the practical significance of her research. At the same time, she is a highly qualified advanced degree scientist with extensive experience in DNA barcoding identification, herbal medicine, supplement quality control, and global biodiversity and conservation.
• Her work has also resulted in 27 peer-reviewed scientific articles and 2 books. Moreover, these papers have been published in some of the most discerning, high-impact journals in her field.
• Indeed, her overall work related to the improvement of DNA barcoding methodology has been cited 641 times by peers using her prior findings to make additional discoveries related to plant taxonomy, DNA barcoding identification systems, and DNA signature development.
• Not only this, but her discoveries have also gone on to influence her peers. That is, researchers have cited her publications in at least 43 countries according to Google Scholar.
• At the same time, she has been called to conduct 18 peer reviews to date, which include prestigious journals of international acclaim in the field.
• These information pieces were followed by a detailed pictorial representation of the countries where her work has been cited.

These related objective pieces of evidence proved her active and actual participation in the field, both as a researcher and reviewer. So, when her NIW petition and later her EB1-A application were placed in front of the adjudicating bench, they reached a decision quickly. Thanks to the premium processing upgrade, her EB1-A petition was approved in just 9 days. We are grateful for having had the trust and thanks of our client throughout the process and having made the approval swift.

---

“I am giving WeGreened (WG) team a 5-star review for my petition’s approval without any RFE. WG team’s remote communication system is very efficient. They guarantee to draft time for the recommendation letters and petition letters. They also perform several rounds of quality checks and they can even catch very minor discrepancies before filing. This team deserves your trust in your immigration journey.”

Case Summary:

When a research scientist II from China hired us to help him in documenting his I-140 NIW (National Interest Waiver) petition back in 2020, we made sure of his credentials and reviewed his proposed research background. We were certain that our unprecedented knowledge in building employment-based visa petitions will gain him the national interest waiver. We proved it right as his NIW petition achieved approval in less than 7 months after we filed his case.

Our satisfied client decided to retain our law firm for filing another petition under the I-140 EB1B (Outstanding Professors and Researchers) visa category since many petitioners get more than one petition filed to increase their chances to move faster to receiving the green card success. Thus, we began accumulating further evidence required for his EB-1B case.

Even though NIW and EB1B are two unique petitions, a few attributes remain the same; the client’s research brief and its impacting factors to the interests of the United States, the publishing record, and citation count. Also, the client’s active participation in the peer review activity. Thus, we outlined the most important aspects of our client’s EB1B case i.e., his research focus on developing new pharmaceutical drugs to prevent and treat life-threatening diseases. We deduced how his research improves disease diagnostics and drug development, as well as how to develop novel drug delivery systems and nano-medicine innovations, confirming that his research is of the utmost importance to major health-related concerns in the United States.

The distinctive point that we highlighted in his EB1B case was his major funding sources; affirmatively his work received funding support from the National Institutes of Health and the United States Department of Defense, therefore, this demonstrates that his work has clearly been recognized as valuable to the national security of the United States.

Also, our aim was to signify his outstanding academic and professional skills set, hence we further included that our client held a Ph.D. in pharmaceutical sciences and published 13 peer-reviewed journal articles in high impact and internationally circulated journals in the field, which altogether accumulated 138 citations from many researchers hailing from several prestigious and widespread institutes in Korea, Denmark, Netherlands, Turkey, Japan, and South Africa, among others. This apparently authenticates the international influence of our client’s work, as well as global implementation of it in the field. Not only did he accomplish his elite level in the field by publishing but also conducted peer reviews, proving his active and actual participation as a judge of the work of other experts in the field. We noted that he had already conducted 80 peer reviews at the time of filing for the petitions.

“[Client] has considerably added value to the existing literature on pharmaceutical sciences through his substantial publication history. He has authored a dozen articles in top-tier scientific journals. These journals only accept exceptional submissions that cover topics on the cutting-edge of research in pharmaceutical sciences. The inclusion of his papers in these periodicals, therefore, highlights the relevance of his work and distinguishes it as being of superior quality.”

The aforementioned excerpt has been contributed by one of his five well-reputed recommenders, concluding that our client has established himself as an instrumental figure within the field of pharmaceutical sciences, and his work has had a resounding influence on the medical community at large. Accordingly, his current research in the United States must continue unimpeded.

We are glad that our client obtained both the petition approvals in the span of 28 days with our team’s efficient efforts in his cases. Our client upgraded his EB-1B case to premium processing, therefore, the case got approved just 7 days after we filed the petition. However, the best part is he got the I-485 approvals even before his EB1B petition approval. We would like to thank him for letting us help him in achieving his green card success. We wish him well in his future endeavors.

---

“Thank you all for your help in securing the I-140.”

General Field: Oncology

Position at the Time of Case Filing: Postdoctoral Fellow

Country of Origin: Ghana

State of Residence at the Time of Filing: Maryland

Approval Notice Date: August 18^th, 2021

Processing Time: 10 months, 19 days

---

“I really enjoyed working with your firm and am extremely satisfied with the quality of the work.”

General Field: Biomedical Engineering

Position at the Time of Case Filing: Scientist

Country of Origin: Iran

State of Residence at the Time of Filing: Florida

Approval Notice Date: June 16^th, 2021

Processing Time: 15 months, 14 days

---

“Thank you for all your help with this petition.”

General Field: Biomedicine

Position at the Time of Case Filing: Postdoctoral Research Fellow

Country of Origin: Turkey

State of Residence at the Time of Filing: Minnesota

Approval Notice Date: August 16^th, 2021

Processing Time: 9 months, 24 days

---

“Great, incomparable value service, which is friendly and available all the time.”

General Field: Biomedical Engineering

Position at the Time of Case Filing: Associate Professor

Country of Origin: Finland

State of Residence at the Time of Filing: Michigan

Approval Notice Date: August 25^th, 2021

Processing Time: 9 months, 26 days

---

“While thanking you for all the fruitful efforts from your team, Many thanks for your support in this regard.”

General Field: Pharmaceutical Sciences

Position at the Time of Case Filing: Pharmaceutical Chemist

Country of Origin: India

State of Residence at the Time of Filing: New Jersey

Approval Notice Date: August 2^nd, 2021

Processing Time: 16 months, 25 days

---